logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
B

Byoung Chul Cho

yonsei university college of medicine
H指数:106
被引数:7.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Brief Report: Patterns of Disease Progression with Durvalumab versus Placebo After Concurrent Chemoradiotherapy for Limited-Stage SCLC in the Phase 3 ADRIATIC Trial

简报：ADRIATIC III期试验中，对于局限期小细胞肺癌经同步化放疗后，度鲁妥单抗与安慰剂治疗的疾病进展模式比较

Journal of Thoracic Oncology
IF20.8
2026-11-030
OA
Suresh Senan; Hongxia Cui; David R. Spigel; Byoung Chul Cho; Konstantin K. Laktionov; Yoshitaka Zenke; Ki Hyeong Lee; Alejandro Navarro; Yoshimasa Shiraishi; Sema Sezgin Goksu; Andrzej Badzio; Anhui Shi; Milada Zemanova; Niels Reinmuth; Puneeth Iyengar; Luis Paz-Ares; Huiling Xiong; W. Victoria Lai; Priti Chugh; Yuanbin Chen
Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study

在随机III期DeLLphi-304研究中，铂类化疗后小细胞肺癌患者接受tarlatamab的延长随访

Annals of Oncology
IF65.4
2026-10-260
OAAI
C.M. Rudin; M-J. Ahn; M. Schuler; F.H. Blackhall; G. Mountzios; T. Yoshida; L. Sun; B.C. Cho; A. Lugini; S. Arulananda; S.R. Punekar; P. Rocha; L. Paz-Ares; J. Mazières; M. Gümüş; U. Demirci; S. Huang; B. Abidi; U. Patil; B. Zhu
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial

在铂类化疗后广泛期小细胞肺癌中使用塔拉他玛单抗的病人报告结局：DeLLphi-304 III期试验结果

Lung Cancer
IF4.4
2026-09-010
PRE
Mountzios, Giannis; Lammers, Philip E.; Sun, Longhua; Cho, Byoung Chul; Demirci, Umut; Arulananda, Surein; Gumus, Mahmut; Punekar, Salman; Lugini, Antonio; Zhu, Bo; Yu, Yan; Ciuleanu, Tudor-Eliade; Ahn, Myung-Ju; Mazieres, Julien; Schuler, Martin; Blackhall, Fiona; Yoshida, Tatsuya; Dirnberger, Franziska; Wang, Jessie; Huang, Shuang; Gauto, Diana; Rudin, Charles M.
Integrative stratification of response to immunotherapy using host and microbial signatures in patients with advanced non-small cell lung cancer

利用宿主和微生物特征对晚期非小细胞肺癌患者免疫治疗反应进行整合分层

Genome Medicine
IF11.2
2026-08-060
OA
Jii Bum Lee; Junwon Yang; Mauricio Chalita; Yeonjae Jung; Haangik Park; Myungja Ro; Hyun Kim; Eunchong Yang; Soeun Choi; Minyoung Kim; Arim Min; Bo-Eun Kwon; Jieun Im; Hyunjeong Kim; Hyunkyung Park; Sun Min Lim; Min Hee Hong; Sein Park; Yeong Ouk Kim; Jongsik Chun; Hyun-Seok Oh; Byoung Chul Cho
A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

SAVANNAH研究的大众语言摘要：色瑞替尼联合奥希替尼用于EGFR突变型晚期非小细胞肺癌患者，这些患者的肿瘤在奥希替尼治疗后出现MET过表达和/或扩增，且肿瘤已进展或扩散。

Future Oncology
IF2.6
2026-07-160
OA
Filippo de Marinis; Tae Min Kim; Laura Bonanno; Susanna Cheng; Sang-We Kim; Marcello Tiseo; Quincy Chu; Claudia Proto; Adrian Sacher; Yung-Hung Luo; Silvia Novello; Desiree Hao; Christina Baik; Lyudmila Bazhenova; Jong Seok Lee; Byoung Chul Cho; Jacques Cadranel; Tuan Bao Diep; Giulio Metro; Prasad Narayanan; Yasuto Yoneshima; Javier de Castro Carpeño; Clarissa Baldotto; James Chih-Hsin Yang; Lecia V. Sequist; Benjamin Levy; Ryan Hartmaier; Ike Igwegbe; Lynne Poole; Wanning Xu; Myung-Ju Ahn
Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

作者勘误：靶向SEZ6的抗体药物偶联物ABBV-706在晚期小细胞肺癌和实体瘤中的研究：一项1期临床试验

Nature Medicine
IF50
2026-06-290
OAAI
Lauren Averett Byers; Byoung Chul Cho; Alissa J. Cooper; Anne C. Chiang; Ji-Youn Han; Muhammad Furqan; Afshin Dowlati; Daniel Morgensztern; Kyriakos P. Papadopoulos; Noura J. Choudhury; María Vieito; Jair Bar; Joo-Hang Kim; Wallace Akerley; Tae Min Kim; Young-Chul Kim; Luis Paz-Ares; Myung-Ju Ahn; Hiroshi Yokouchi; Darius Meiman; Wijith Munasinghe; Oluwadamilola Ogunyankin; Nadine Jahchan; Song Wang; Cristiano Ferlini; Randy R. Robinson; Frederick J. Kohlhapp; Tammy Palenski; Guillermo Rivell; Pooja Hingorani; Sreenivasa Chandana
Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

度鲁妥单抗联合依托泊苷-铂类方案用于表皮生长因子受体（EGFR）突变型晚期非小细胞肺癌（NSCLC）并在接受奥希替尼一线治疗后发生神经内分泌转化的患者：ORCHARD研究

Lung Cancer
IF4.4
2026-06-180
PRE
Isamu Okamoto; Byoung Chul Cho; Sarah B. Goldberg; Jonathan W. Goldman; Adrianus J. de Langen; Zofia Piotrowska; Jonathan W. Riess; Helena A. Yu; MRosario Garcia Campelo; Jeremy Cetnar; Yu Jung Kim; Silvia Novello; Yoshimasa Shiraishi; Helen Ambrose; Paul E. Smith; Kwan Ho Tang; Jonathan M. Lehman; Xiuning Le
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

奥希替尼联合塞尔鲁替尼在既往一线奥希替尼进展后EGFR突变型晚期NSCLC伴BRAF突变患者中的疗效：ORCHARD研究

European Journal of Cancer
IF7.1
2026-05-180
PRE
Zofia Piotrowska; Sarah B. Goldberg; Jonathan W. Goldman; Adrianus J. de Langen; Xiuning Le; Isamu Okamoto; Jonathan W. Riess; Helena A. Yu; Kazumi Nishino; Silvia Novello; Santiago Ponce; Helen Ambrose; Paul. E. Smith; Kwan Ho Tang; Jonathan. M. Lehman; Byoung Chul Cho
MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer

MORPHEUS-Lung：转移性非小细胞肺癌患者中阿替利珠单抗联合贝伐珠单抗联合立体定向体部放射治疗的生物标志物和临床反应

Lung Cancer
IF4.4
2026-05-070
PRE
Byoung Chul Cho; Sun Min Lim; Sang Hoon Lee; Dong Kwon Kim; Nuria Pardo; Hen Prizant; Yaacov R. Lawrence; Nedal Al-Sakaff; Hans-Joachim Helms; Velimir Gayevskiy; Barzin Y. Nabet; Jan Pintoffl; Francois Ghiringhelli
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies

度伐利尤单抗，一种人淋巴细胞活化基因-3单克隆抗体，与西米普利单抗联合：在晚期恶性肿瘤中的肿瘤特异性扩展队列

Cancer
IF5.1
2026-04-240
OAAI
Tae Min Kim MD, PhD; Stephen K. Williamson MD; Kyriakos P. Papadopoulos MD; Omid Hamid MD; Grace K. Dy MD; Ray McDermott MD; Ariel Birnbaum MD; John M. Kaczmar MD; Nehal Lakhani MD; Danny Rischin MD; Debashis Sarker MD; Afshin Dowlati MD; Xin-Hua Zhu MD; Jyoti Malhotra MD; Jean-Francois Pouliot PhD; Jayakumar Mani PhD; Laura Brennan DrPH; Fang Fang PhD; Shuquan Chen PhD; Mark Salvati PhD; Israel Lowy MD; Ahmed Khaled MD; Karl D. Lewis MD; Glenn Kroog MD; Matthew G. Fury MD, PhD; Byoung Chul Cho MD
Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes

基于组织病理学分期和EGFR分子亚型的EGFR突变非小细胞肺癌（NSCLC）的分子与临床差异

Translational Lung Cancer Research
IF3.5
2026-03-230
PRE
Yoon, Dayoung; Lee, Ji Won; Cho, Byoung Chul; Kang, Eun Joo; Kim, Jung Sun; Lim, Taekyu; Yi, Seong Yoon; Kim, Yu Jung; Ahn, Mi Sun; Kim, Young Saing; Park, Ji Hyun; Lim, Seungtaek; Park, Hyung Soon; Cho, Jang Ho; Jang, Byunghyun; Lee, Ji Yoon; Kim, Jiwon; Hong, Jisoo; Koo, Harim; Chung, Seok; Shin, Sang Won; Kim, Yeul Hong; Sa, Jason K.; Choi, Yoon Ji
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Lung Cancer
IF4.4
2026-02-040
PRE
Hidetoshi Hayashi; Byoung Chul Cho; Yu Jung Kim; Se-Hoon Lee; Pongwut Danchaivijitr; Adlinda Alip; Hailin Xiong; Soon-Hin How; Gee-Chen Chang; James Chih-Hsin Yang; Yuta Yamanaka; Mehmet Ali Nahit Şendur; Kumar Prabhash; Koichi Azuma; Alianu Akawung; Elizabeth Fennema; Xiaodan Tang; Sujay Shah; Seema Sethi; Shun Lu
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Amivantamab联合化疗与化疗一线治疗EGFR外显子20插入突变的晚期非小细胞肺癌患者: PAPILLON Asia亚组分析

Lung Cancer
IF4.4
2026-02-020
PRE
Caicun Zhou; Ke-Jing Tang; Baogang Liu; Sang-We Kim; Satoru Kitazono; Akira Ono; Muthukkumaran Thiagarajan; Jen-Yu Hung; Michael Boyer; Timuçin Çİl; Yu Yao; Rajnish Nagarkar; John Xie; Archan Bhattacharya; Honeylet Wortman-Vayn; Mahadi Baig; Trishala Agrawal; Patricia Lorenzini; Se-Hoon Lee; Byoung Chul Cho

研究方向

暂未获取到该数据
M
Min Hee Hong
H 指数:39论文数:657被引数:6,623
H
Hye Ryun Kim
H 指数:60论文数:749被引数:1.8万
S
Sun Min Lim
H 指数:33论文数:560被引数:4,289
K
Kyoung‐Ho Pyo
H 指数:26论文数:242被引数:2,416
M
Mi Ran Yun
H 指数:28论文数:282被引数:2,148
E
Enriqueta Felip
H 指数:129论文数:1,499被引数:11.1万
J
Jii Bum Lee
H 指数:15论文数:190被引数:980
M
Myung‐Ju Ahn
H 指数:109论文数:1,300被引数:7.2万
J
Jae Hwan Kim
H 指数:21论文数:226被引数:1,559
H
Hyo Sup Shim
H 指数:45论文数:266被引数:7,248